Bellbrook Labs, LLC — Department of Health and Human Services STTR Phase I: 300

Bellbrook Labs, LLC — STTR Phase I award from Department of Health and Human Services.

Amount
$234,936
Agency
Department of Health and Human Services · National Institutes of Health
Program / Phase
STTR · Phase I
Topic
300
Solicitation
PA15-270
NAICS
Place of performance
WI
Period
2016-09-13 → 2019-03-31

Description

Project Summary Abstract High throughput screening HTS is a powerful method for the discovery of new drug leads for target enzymes In HTS assays the activity of the target enzyme is often evaluated by quantifying a small molecule or cofactor that is produced or consumed by the enzyme While antibodies are a mainstay of small molecule detection as says they do have severe limitations which are largely tied the challenge of functionalizing small molecule targets without masking key functional groups As a result conjugation of the target molecule to a carrier pro tein for antibody generation is laborious and often decreases the specificity of the antibodies generated Addi tionally HTS assays that use small molecule binding antibodies require that a labeled version of the target be produced to act as a competitor in the assay We propose that DNA structure switching SS biosensors can overcome these limitations as these sensors provide a direct fluorescence readout upon target binding and do not require that the target be covalently labeled Additionally these biosensors utilize nucleic acid ap tamers which can be generated using in vitro selection methods that do not necessarily require that the target be modified or immobilized While SS biosensors hold tremendous potential for use in HTS and other small molecule detection assays the currently available protocols for generating these biosensors are time consuming and at times unreliable Thus we propose an improved method for the in vitro selection of SS bio sensors that is anticipated to provide more efficient enrichment of functional sequences This will both reduce the time required and increase the success rate for generating biosensors to new small molecule targets of interest In Aim we will develop and implement this selection method to generate a SS biosensor for Coen zyme A CoA In Aim we will utilize this biosensor to produce a fluorescence polarization HTS assay for CoA the product of histone acetyltransferases HATs The immediate impact of this research will be an im proved HTS assay for screening HATs which will address a significant unmet need in drug discovery for a number of epigenetic diseases including neurological disorders cancers and cardiovascular disease From a broader perspective this research will provide a rapid and reliable method for generating SS biosensors for small molecule targets which will accelerate development of HTS assays for diverse enzyme drug targets Project Narrative High throughput screening HTS has proven to be a highly effective method for drug discovery The proposed research will develop new methods for HTS against protein targets that play key roles in multi ple diseases with an initial focus on diseases with an epigenetic basis